

REMARKS

The amendment does not introduce new matter within the meaning of 35 U.S.C. §132. Accordingly, the Examiner is respectfully requested to enter the above amendments before examination.


The Examiner is invited to telephone the undersigned attorney if she has any questions or comments.

Respectfully submitted,

NATH & ASSOCIATES PLLC

Date: May 1, 2002

NATH & ASSOCIATES PLLC
1030 15th Street, N.W.
6th Floor
Washington, D.C. 20005
Tel: (202) 775-8383
Fax: (202) 775-8396
GMN:TLJ/SMM\amend.final.wpd



Gary M. Nath
Reg. No. 26,965
Todd L. Juneau
Reg. No. 40,669
Customer No. 20529

Appendix A

· ("mark-up" copy of amended claims)

8. (Once amended) A [pharmaceutical] composition comprising the combination product of claim 5 and further comprising a pharmaceutically acceptable diluent or carrier.

14. (Once amended) A [pharmaceutical] composition, comprising an antisense deoxyoligonucleotide having a sequence according to SEQ ID No. 1 or SEQ ID No. 2, and further comprising a pharmaceutically acceptable carrier or diluent.

Appendix B
("clean" copy of amended claims)

C¹
8. A composition comprising the combination product of claim 5 and further comprising a pharmaceutically acceptable diluent or carrier.

C²
14. A composition, comprising an antisense deoxyoligonucleotide having a sequence according to SEQ ID No. 1 or SEQ ID No. 2, and further comprising a pharmaceutically acceptable carrier or diluent.